0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon-α in Chronic Hepatitis C

Liliana Chemello, MD, PhD; Luisa Cavalletto, MD; Carla Casarin, MD; Paola Bonetti, MD; Elisabetta Bernardinello, MD; Patrizia Pontisso, MD; Carlo Donada, MD; Fabio Belussi, MD; Silio Martinelli, MD; and Alfredo Alberti, MD
[+] Article and Author Information

The TriVeneto Viral Hepatitis Group From the University of Padova, Padova, Italy; O.C. Pordenone, Pordenone, Italy; O. Le Grazie, Venezia, Italy; and O.C. Cittadella, Cittadella, Italy. Grant Support: In part by grant 407/01/94 from Ricerca Sanitaria Finalizzata-Regione Veneto. Requests for Reprints: Alfredo Alberti, MD, Clinica Medica 2, via Giustiniani 2, 35100 Padova, Italy. Current Author Addresses: Drs. Chemello, Cavalletto, Casarin, Bonetti, Bernadinello, Pontisso, and Alberti: Clinica Medica 2, University of Padova, via Giustiniani 2, 35100 Padova, Italy. Dr. Donada: III Divisione Medica, O.C. Pordenone, via Monteverde, 33170 Pordenone, Italy.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1996;124(12):1058-1060. doi:10.7326/0003-4819-124-12-199606150-00005
Text Size: A A A

Objective: To define long-term outcome in patients with chronic hepatitis C who remain viremic after sustained biochemical response to interferon-α therapy.

Design: Prospective evaluation of an outpatient cohort.

Setting: University hospital.

Patients: 107 patients with chronic hepatitis C who maintained normal aminotransferase levels as long as 12 months after interferon-α therapy. Patients were followed prospectively for an additional 6 to 36 months.

Measurements: Aminotransferase levels were monitored at 3-month intervals. Serum hepatitis C virus (HCV) RNA was tested by polymerase chain reaction before therapy, at the end of therapy, and 12 months after therapy. The HCV genotype was defined by spot hybridization using serum specimens obtained before treatment.

Results: Hepatitis C virus RNA was detected in 27 (25%) patients with sustained biochemical response; 80 (75%) patients were negative for HCV RNA. Patients positive for HCV RNA were older (P < 0.001), had received a smaller interferon-α dose (P = 0.02), and were more frequently infected with HCV genotype 2 (P < 0.01). Liver histologic findings were active in 57% of patients positive for HCV RNA, despite normal alanine aminotransferase levels, compared with only 12% of patients who were negative for HCV RNA (P = 0.01). The estimated probability of hepatitis relapse by 4 years after therapy was 53% in viremic patients and 0% in patients negative for HCV RNA (P < 0.001).

Conclusion: Patients with chronic hepatitis C should be tested for serum HCV RNA 1 year after a sustained biochemical response to interferon-α therapy to determine whether the response is complete and permanent.

Figures

Grahic Jump Location
Figure 1.
Probability of maintaining normal serum alanine aminotransferase levels at long-term follow-up (Kaplan-Meier curves).P

The line with asterisks represents patients who were negative for hepatitis C virus RNA (HCV-RNA), and the solid line represents patients who were positive and had a sustained biochemical response to interferon-α as long as 12 months after discontinuation of therapy. In viremic patients, the estimated probability of hepatitis relapse is 53% 4 years after therapy; in HCV RNA-negative patients, the probability is 0% (log-rank test; < 0.001).

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)